Steven C Campbell

Summary

Affiliation: Cleveland Clinic Foundation
Country: USA

Publications

  1. doi request reprint The use of zoledronic acid in men receiving androgen deprivation therapy for prostate cancer with severe osteopenia or osteoporosis
    Steven C Campbell
    Edward Hines Jr VA Hospital, Hines, Illinois, USA
    Urology 75:1138-43. 2010
  2. doi request reprint Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy
    Nirmala Bhoopalam
    Edward Hines, Jr Veterans Affairs Hospital, Hines, Illinois 60141, USA
    J Urol 182:2257-64. 2009
  3. doi request reprint Small renal masses: toward more rational treatment
    Anil A Thomas
    Glickman Urological and Kidney Institute, Cleveland, OH 44195, USA
    Cleve Clin J Med 78:539-47. 2011
  4. ncbi request reprint Prostate-sparing cystectomy: has Pandora's box been opened?
    John C Kefer
    Glickman Urological Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Expert Rev Anticancer Ther 7:1003-14. 2007
  5. doi request reprint Management of the adrenal gland during partial nephrectomy
    Brian R Lane
    Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA
    J Urol 181:2430-6; discussion 2436-7. 2009
  6. doi request reprint Laparoendoscopic single-site radical cystectomy and pelvic lymph node dissection: initial experience and 2-year follow-up
    Jihad H Kaouk
    Section of Laparoscopic and Robotic Surgery, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio, USA
    Urology 76:857-61. 2010
  7. doi request reprint Effect of parenchymal volume preservation on kidney function after partial nephrectomy
    Matthew N Simmons
    Section of Urologic Oncology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA
    J Urol 186:405-10. 2011
  8. doi request reprint Salvage of local recurrence after primary thermal ablation for small renal masses
    Carvell T Nguyen
    Glickman Urological and Kidney Institute, Cleveland Clinic Foundation, 9500 Euclid Avenue, A100 Cleveland, OH 44195, USA
    Expert Rev Anticancer Ther 8:1899-905. 2008
  9. doi request reprint Surgical salvage of renal cell carcinoma recurrence after thermal ablative therapy
    Carvell T Nguyen
    Glickman Urological and Kidney Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    J Urol 180:104-9; discussion 109. 2008
  10. doi request reprint Current status of prostate-sparing cystectomy
    John C Kefer
    Glickman Urological Institute, Cleveland Clinic, Cleveland, OH 44195, USA
    Urol Oncol 26:486-93. 2008

Detail Information

Publications43

  1. doi request reprint The use of zoledronic acid in men receiving androgen deprivation therapy for prostate cancer with severe osteopenia or osteoporosis
    Steven C Campbell
    Edward Hines Jr VA Hospital, Hines, Illinois, USA
    Urology 75:1138-43. 2010
    ..The effect of zoledronic acid on patients with pre-existing osteoporosis on ADT, who are highest risk for fracture, has not been adequately studied...
  2. doi request reprint Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy
    Nirmala Bhoopalam
    Edward Hines, Jr Veterans Affairs Hospital, Hines, Illinois 60141, USA
    J Urol 182:2257-64. 2009
    ..There are limited data on patients on prolonged androgen deprivation therapy or in Veterans Affairs patients with multiple risk factors for osteoporosis...
  3. doi request reprint Small renal masses: toward more rational treatment
    Anil A Thomas
    Glickman Urological and Kidney Institute, Cleveland, OH 44195, USA
    Cleve Clin J Med 78:539-47. 2011
    ..Renal mass biopsy with molecular profiling will likely allow for more rational treatment in the near future...
  4. ncbi request reprint Prostate-sparing cystectomy: has Pandora's box been opened?
    John C Kefer
    Glickman Urological Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Expert Rev Anticancer Ther 7:1003-14. 2007
    ..The concept of PSCx is arguably one of the most controversial topics in the field of bladder cancer today...
  5. doi request reprint Management of the adrenal gland during partial nephrectomy
    Brian R Lane
    Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA
    J Urol 181:2430-6; discussion 2436-7. 2009
    ..We analyzed initial management and oncological outcomes of adrenal glands after open partial nephrectomy...
  6. doi request reprint Laparoendoscopic single-site radical cystectomy and pelvic lymph node dissection: initial experience and 2-year follow-up
    Jihad H Kaouk
    Section of Laparoscopic and Robotic Surgery, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio, USA
    Urology 76:857-61. 2010
    ..The development of laparoendoscopic single-site surgery and its application to urothelial malignancy has not been previously evaluated...
  7. doi request reprint Effect of parenchymal volume preservation on kidney function after partial nephrectomy
    Matthew N Simmons
    Section of Urologic Oncology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA
    J Urol 186:405-10. 2011
    ..We assessed what is to our knowledge a novel method to estimate the percent of functional volume preservation to assess its effect on functional outcomes...
  8. doi request reprint Salvage of local recurrence after primary thermal ablation for small renal masses
    Carvell T Nguyen
    Glickman Urological and Kidney Institute, Cleveland Clinic Foundation, 9500 Euclid Avenue, A100 Cleveland, OH 44195, USA
    Expert Rev Anticancer Ther 8:1899-905. 2008
    ..We provide, herein, an assessment of the efficacy and limitations of primary thermal ablation and strategies for salvage treatment of local recurrence in this growing patient population...
  9. doi request reprint Surgical salvage of renal cell carcinoma recurrence after thermal ablative therapy
    Carvell T Nguyen
    Glickman Urological and Kidney Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    J Urol 180:104-9; discussion 109. 2008
    ..However, initial data have suggested higher local recurrence rates for ablation compared to partial nephrectomy. We evaluated options for salvage of ipsilateral tumor recurrence after previous ablation...
  10. doi request reprint Current status of prostate-sparing cystectomy
    John C Kefer
    Glickman Urological Institute, Cleveland Clinic, Cleveland, OH 44195, USA
    Urol Oncol 26:486-93. 2008
    ..Prostate-sparing cystectomy is arguably one of the most controversial topics in the field of urology today...
  11. doi request reprint Choice of operation for clinically localized renal tumor
    Carvell T Nguyen
    Glickman Urological and Kidney Institute, Cleveland Clinic Foundation, 9500 Euclid Avenue A100, Cleveland, OH 44195, USA
    Urol Clin North Am 35:645-55; vii. 2008
    ..In all these discussions we assume that a proactive approach to treatment is indicated and desired, recognizing that active surveillance is always an additional option to consider in certain subpopulations such as the elderly or infirm...
  12. ncbi request reprint Perioperative outcomes with laparoscopic radical cystectomy: "pure laparoscopic" and "open-assisted laparoscopic" approaches
    Georges Pascal Haber
    Section of Laparoscopic and Robotic Surgery, Glickman Urological Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA
    Urology 70:910-5. 2007
    ..We retrospectively evaluated the outcomes of these two techniques with a focus on perioperative outcomes and associated morbidity...
  13. ncbi request reprint Presentation, location and overall survival of pelvic recurrence after radical cystectomy for transitional cell carcinoma of the bladder
    Nivedita Bhatta Dhar
    Section of Urologic Oncology, Glickman Urological Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    BJU Int 101:969-72. 2008
    ..To evaluate the presentation, location and overall survival of pelvic recurrence after radical cystectomy (RC) for transitional cell carcinoma (TCC) of the bladder...
  14. ncbi request reprint Risk assessment for occult malignancy in the prostate before radical cystectomy
    John C Kefer
    Department of Urology, Loyola University Medical Center, Maywood, Illinois, USA
    Urology 66:1251-5. 2005
    ..To assess our clinical ability to predict prostate involvement by transitional cell carcinoma (PI-TCC) or occult prostate cancer (CAP) in patients undergoing radical cystectomy (RCx)...
  15. doi request reprint Surgical resection of renal cell carcinoma after targeted therapy
    Anil A Thomas
    Glickman Urological and Kidney Institute, Cleveland, Ohio 44195, USA
    J Urol 182:881-6. 2009
    ..The integration of targeted therapy and surgery requires careful consideration due to the potential for increased perioperative morbidity...
  16. ncbi request reprint Renal cell carcinoma
    Brian I Rini
    Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, USA
    Curr Opin Oncol 18:289-96. 2006
    ..In addition, this review will update recent advances in diagnostic and imaging modalities for renal cell carcinoma and dietary and environmental relationships to the epidemiology of this growing disease...
  17. ncbi request reprint Outcomes in patients with urothelial carcinoma of the bladder with limited pelvic lymph node dissection
    Nivedita Bhatta Dhar
    Section of Urologic Oncology, Glickman Urological Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    BJU Int 98:1172-5. 2006
    ..To evaluate the rates of local and systemic progression (LP and SP), recurrence-free survival and overall survival for patients with urothelial carcinoma of the bladder with limited pelvic lymph node dissection (PLND) in 1987-2000...
  18. doi request reprint Nephrectomy induced chronic renal insufficiency is associated with increased risk of cardiovascular death and death from any cause in patients with localized cT1b renal masses
    Christopher J Weight
    Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA
    J Urol 183:1317-23. 2010
    ..Therefore, we compared overall survival, cancer specific survival and cardiac specific survival in patients undergoing partial or radical nephrectomy for cT1b tumors...
  19. doi request reprint Lack of pathologic down-staging with neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma of the bladder: a contemporary series
    Christopher J Weight
    Glickman Urologic and Kidney Institute, Cleveland Clinic, Cleveland, Ohio 44195 0001, USA
    Cancer 115:792-9. 2009
    ..The outcome of NC and open radical cystectomy (RC) was evaluated in a contemporary cohort of patients in a tertiary referral setting...
  20. ncbi request reprint Integration of surgery and systemic therapy in the management of metastatic renal cancer
    Anil A Thomas
    Glickman Urological and Kidney Institute, Cleveland Clinic Foundation, Desk A100, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Curr Urol Rep 10:35-41. 2009
    ..Relevant issues in this era relate to the timing of surgery, the role of cytoreduction as systemic therapies become more effective, management of the residual mass, and surgical safety after targeted therapy...
  21. doi request reprint Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma
    Anil A Thomas
    Glickman Urological and Kidney Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    J Urol 181:518-23; discussion 523. 2009
    ..We assessed the activity of neoadjuvant sunitinib on primary renal tumors in patients with advanced renal cell carcinoma as well as the feasibility and safety of subsequent surgical resection...
  22. doi request reprint Association of percentage of tumour burden removed with debulking nephrectomy and progression-free survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy
    Juan Barbastefano
    Department of Medicine, Cleveland Clinic, Cleveland, OH, USA
    BJU Int 106:1266-9. 2010
    ....
  23. doi request reprint Aggregate lymph node metastasis diameter and survival after radical cystectomy for invasive bladder cancer
    Andrew J Stephenson
    Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA
    Urology 75:382-6. 2010
    ..The aggregate LN metastasis diameter (ALNMD) may better reflect the burden of metastatic disease and improve the ability to predict recurrence-free (RFS) and overall survival (OS)...
  24. doi request reprint Clinicopathologic features and utility of immunohistochemical markers in signet-ring cell adenocarcinoma of the bladder
    Anil A Thomas
    Glickman Urological and Kidney Institute, The Cleveland Clinic, Cleveland, OH 44195, USA
    Hum Pathol 40:108-16. 2009
    ....
  25. ncbi request reprint The evolving role of surgery for advanced renal cell carcinoma in the era of molecular targeted therapy
    Brian I Rini
    Department of Solid Tumor Oncology and Urology, Cleveland Clinic Taussig Cancer Center and Section of Urological Oncology, Glickman Urological Institute, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    J Urol 177:1978-84. 2007
    ..Accomplishing this in the current era of targeted molecular therapies presents unique challenges and opportunities...
  26. doi request reprint Clinical correlates of renal angiomyolipoma subtypes in 209 patients: classic, fat poor, tuberous sclerosis associated and epithelioid
    Brian R Lane
    Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA
    J Urol 180:836-43. 2008
    ..We investigated the clinical, radiographic and histological characteristics of each angiomyolipoma subtype...
  27. ncbi request reprint A preoperative prognostic nomogram for solid enhancing renal tumors 7 cm or less amenable to partial nephrectomy
    Brian R Lane
    Glickman Urological Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA
    J Urol 178:429-34. 2007
    ..We present novel nomograms that predict the likelihood of benign, likely indolent or potentially aggressive pathological findings based only on readily identifiable preoperative factors...
  28. doi request reprint Active treatment of localized renal tumors may not impact overall survival in patients aged 75 years or older
    Brian R Lane
    Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA
    Cancer 116:3119-26. 2010
    ....
  29. doi request reprint Elective partial nephrectomy in patients with clinical T1b renal tumors is associated with improved overall survival
    Christopher J Weight
    Glickman Urologic and Kidney Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA
    Urology 76:631-7. 2010
    ..PN may offer the perfect combination of cancer control and preservation of renal function; therefore we compared overall and cancer-specific survival in patients treated for cT1b renal masses...
  30. ncbi request reprint Targeted molecular therapy for renal cell carcinoma
    Brian R Lane
    Glickman Urological Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Urology 69:3-10. 2007
  31. doi request reprint Chronic kidney disease after nephroureterectomy for upper tract urothelial carcinoma and implications for the administration of perioperative chemotherapy
    Brian R Lane
    Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA
    Cancer 116:2967-73. 2010
    ..Although multimodal treatment paradigms for UTUC are under-developed, this has important implications on patients' ability to receive cisplatin-based combination chemotherapy (CBCC)...
  32. doi request reprint Current trends in the management of bladder cancer
    Amit R Patel
    Glickman Urological and Kidney Institute, The Cleveland Clinic, Ohio 44195, USA
    J Wound Ostomy Continence Nurs 36:413-21; quiz 422-3. 2009
    ..Newer therapies involving novel molecular-targeted agents provide hope for the future for patients with metastatic disease...
  33. ncbi request reprint Screening for urologic malignancies in primary care: pros, cons, and recommendations
    Andrew J Stephenson
    Section of Urologic Oncology, Glickman Urological Institute, Cleveland Clinic, Cleveland, OH 44195, USA
    Cleve Clin J Med 74:S6-14. 2007
    ....
  34. ncbi request reprint Laparoscopic radical cystectomy
    Monish Aron
    Section of Laparoscopic and Robotic Surgery, Glickman Urological Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    BJU Int 100:455-76. 2007
  35. ncbi request reprint Staging of renal cell carcinoma: past, present, and future
    Carvell T Nguyen
    Glickman Urological Institute, Cleveland Clinic Foundation, OH 44195, USA
    Clin Genitourin Cancer 5:190-7. 2006
    ..Finally, a glimpse into the future of staging of RCC will be offered with a discussion of integrated staging and prognostic systems...
  36. doi request reprint Laparoscopic radical cystectomy: current status, outcomes, and patient selection
    Brian H Irwin
    Department of Urology, Center for Laparoscopic and Robotic Surgery, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH 44195, USA
    Curr Treat Options Oncol 10:243-55. 2009
    ....
  37. doi request reprint Renal cell carcinoma
    Brian I Rini
    Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA
    Lancet 373:1119-32. 2009
    ..Targeted drugs, including inhibitors of the vascular endothelial growth factor and mammalian target of rapamycin pathways, have shown robust effectiveness and offer new therapeutic options for the patients with metastatic disease...
  38. doi request reprint Gonadal vein tumor thrombus in metastatic renal cell carcinoma
    Anil A Thomas
    Glickman Urological and Kidney Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Urology 73:1229-30. 2009
    ..We present a case of a patient with unresectable metastatic renal cell carcinoma invading the gonadal vein, who was initially treated with targeted molecular therapy...
  39. ncbi request reprint The paradigm shift in renal mass biopsy
    Steven C Campbell
    Section of Urological Oncology, Glickman Urological Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Clin Adv Hematol Oncol 6:253-4, 258. 2008
  40. ncbi request reprint Renal mass biopsy--a renaissance?
    Brian R Lane
    Glickman Urological Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA
    J Urol 179:20-7. 2008
    ....
  41. ncbi request reprint Renal medullary carcinoma and ABL gene amplification
    Lijo Simpson
    Department of Medicine, Illinois Masonic Medical Center, Maywood, Illinois, USA
    J Urol 173:1883-8. 2005
    ..We characterized the clinical course of renal medullary carcinoma (RMC) and performed an expanded analysis of BCR-ABL...
  42. doi request reprint Performance of the chronic kidney disease-epidemiology study equations for estimating glomerular filtration rate before and after nephrectomy
    Brian R Lane
    Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA
    J Urol 183:896-901. 2010
    ..We compared the estimated glomerular filtration rate using several serum creatinine based formulas against the measured rate based on (125)I-iothalamate clearance to determine which most accurately reflects the rate in this setting...
  43. doi request reprint Adult cystic nephroma and mixed epithelial and stromal tumor of the kidney: clinical, radiographic, and pathologic characteristics
    Brian R Lane
    Glickman Urological Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Urology 71:1142-8. 2008
    ..Clinical and radiographic data regarding these lesions are sparse, especially with respect to factors providing clinical suspicion for CN or MEST...